Twist Bioscience Stock Rallies On AI Deals And Analyst Upgrades

Twist Bioscience Corporation stocks have been trading up by 7.42 percent following upbeat coverage of its synthetic biology innovations.

Live Update At 12:32:59 EDT: On Monday, October 05, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 7.42%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TWST has turned into a momentum rollercoaster, and the numbers back that up. On the chart, Twist Bioscience ran from a close of $126.85 on 2026/09/10 to $202.68 on 2026/10/05. That’s a huge move in less than a month, driven by AI headlines and analyst upgrades.

Recent daily action shows higher highs and higher lows, a classic uptrend. Pullbacks toward the mid-$180s to $190s have been getting bought, with TWST snapping back and printing new short-term highs. Intraday on 2026/10/05, the stock opened near $189 and pushed above $203 before consolidating around $202, showing strong dip support and steady buying on every fade.

Fundamentally, Twist Bioscience is still losing money. Quarterly revenue sits around $118.4M, with gross margin near 52% but an EBIT margin of about -32% and a net loss near $35.1M. Cash burn remains real, with free cash flow around -$8.6M in the latest quarter. But TWST holds roughly $166.8M in cash and short-term investments, a current ratio of 2.7, and modest leverage, giving it runway.

For traders, the key is this mix: strong top-line growth, improving margins, and a clear target of adjusted EBITDA breakeven by Q4 FY26. That combination can keep momentum traders circling the name, even while traditional value metrics like price-to-sales near 29 look stretched.

Why Traders Are Watching TWST Right Now

Twist Bioscience has put itself right in the middle of one of the hottest narratives in the market: AI-powered drug discovery. TWST signed an agreement to provide antibody characterization data and services to Eli Lilly’s TuneLab, an AI/ML drug discovery platform that leans on models like AbLab. In plain English, Lilly’s algorithms need clean, high-quality lab data, and Twist Bioscience is becoming the pipeline that feeds those models.

This is exactly the kind of “picks-and-shovels” position active traders like to see. TWST is not trying to guess the next blockbuster drug. Instead, it sells the tools and data big pharma needs to do that guessing at scale. Integrating Twist Bioscience’s protocols directly into TuneLab means Lilly’s users can order antibody services that automatically plug into the AI workflow. That deepens lock-in, expands data volume, and can translate into sticky, recurring demand.

The tape confirms how the market feels about this. Multiple reports note TWST shares jumped and rose over 4% intraday after the Lilly deal was announced on 2026/09/16, with follow‑through gains as traders digested the story. Later in September, Twist Bioscience climbed another 6.9% to $169.38 even on a quieter news day, suggesting that sentiment and technicals are reinforcing the fundamental story.

Analysts are piling on. Leerink has raised its TWST target twice in quick succession, first to $160, then to $190, while keeping an Outperform stance. Guggenheim went even further, more than doubling its target from $107 to $212 ahead of Q3 earnings. Both are signaling that the Street had been too conservative on revenue and underappreciated pharma adoption of the Twist Bioscience platform and its AI angle.

There are nuances traders should not ignore. TWST confirmed that its pilot work making AI-designed mini‑binder proteins for Anthropic is already “probably sort of” baked into its fiscal 2027 order outlook. That means the project is real, but it is not some hidden upside bomb waiting to explode numbers higher. UBS also initiated at Neutral with a $144 target, a reminder that some on the Street see valuation risk after this big run.

Even insider and ownership moves are in play. CEO Emily Leproust sold 5,203 shares worth roughly $923,000 but still holds over 613,000 shares, so she remains heavily exposed to TWST’s long-term outcome. Meanwhile, an amended Schedule 13G/A showed changes in a major holder’s passive stake, signaling ongoing institutional activity around Twist Bioscience.

For short-term traders, this backdrop means TWST is a liquid, news-sensitive name where AI headlines, price‑target hikes, and large block activity can all spark sharp intraday moves. For longer‑term swing traders, the Lilly TuneLab deal and AI protein projects build a case that Twist Bioscience is becoming core infrastructure in a fast‑growing niche.

Conclusion

Twist Bioscience has shifted from a niche synthetic biology story to a frontline AI‑drug‑discovery infrastructure play. TWST’s partnership with Eli Lilly’s TuneLab gives the company real-world proof that its wet‑lab capabilities are critical to high‑end AI models like AbLab. When you layer that onto strong revenue growth, expanding gross margins, and a stated path to adjusted EBITDA breakeven in Q4 FY26, you can see why the stock has been on a tear.

The valuation is not cheap. With a price-to-sales ratio pushing near 29 and negative earnings, TWST is being priced as a high‑growth, high‑expectation name. Guggenheim’s $212 target and Leerink’s $190 target show just how far the bullish camp thinks Twist Bioscience can run. At the same time, UBS’s Neutral at $144 and the reality of ongoing cash burn remind traders that execution risk and macro shocks still matter.

For active traders, TWST is now a classic momentum plus catalyst setup. The chart is trending, the story is hot, and the flow of news — from TuneLab, to Anthropic mini‑binders, to repeated analyst upgrades — keeps refreshing the narrative. That’s exactly the kind of environment where disciplined planning is essential. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” That kind of discipline around entries and exits is critical when navigating fast-moving names like TWST.

Tim Sykes is blunt about names like this: “Hype comes and goes, but risk management is forever. I don’t care how hot the story is — rule number one is always cut losses quickly.” For anyone trading Twist Bioscience, that mindset belongs on the screen right next to the TWST ticker.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks